Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Dexamethasone Added to Induction and Post-remission Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT03609060 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT03609060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03609060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Dexamethasone Added to Induction and Post-remission Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 24, 2018
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia